Arbutus Biopharma (ABUS) earnings history
Most recent quarter
- Fiscal period
- Q2 2025
- Period end
- Jun 30, 2025
- EPS actual
- $0.01
- EPS estimate
- −$0.05
- EPS surprise
- +121.05%
- Revenue surprise
- +574.98%
- Revenue
- $10.7M
- Revenue estimate
- $1.6M
- Reported
- Aug 6, 2025
Arbutus Biopharma's most recent quarter in the table is Q2 2025, reported August 6, 2025. EPS was $0.01, against an expected loss of $0.05, a 121.05% beat. Revenue was $10.7 million, far above the $1.6 million estimate, a 574.98% surprise. A year earlier, in Q2 2024, the company lost $0.11 per share on revenue of $1.7 million.
Q2 2025 was the only profitable quarter of the 20 shown; the other 19 were losses. The annual loss per share narrowed each year, from $0.83 in 2021 to $0.46 in 2022, $0.44 in 2023 and $0.38 in 2024. Revenue has moved unevenly, from a table high of $14.2 million in Q2 2022 to a low of $1.3 million in Q3 2024, with full-year revenue of $39.0 million in 2022 and $6.1 million in 2024. Arbutus beat EPS estimates in 11 of the 20 quarters.
The table has no quarter after Q2 2025. In earlier years, third-quarter results came between November 4 and November 9, and fourth-quarter results between late February and late March. The next quarter added here will show whether the Q2 2025 profit was repeated or stood as a single result.
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2025 | Aug 6, 2025 | −$0.05 | $0.01 | +121.05% | $10.7M | SEC |
| Q1 2025 | May 14, 2025 | −$0.10 | −$0.13 | −25.00% | $1.8M | SEC |
| Q4 2024 | Mar 27, 2025 | −$0.08 | −$0.07 | +12.50% | $1.6M | SEC |
| Q3 2024 | Nov 6, 2024 | −$0.09 | −$0.10 | −6.38% | $1.3M | SEC |
| Q2 2024 | Aug 1, 2024 | −$0.10 | −$0.11 | −14.58% | $1.7M | SEC |
| Q1 2024 | May 2, 2024 | −$0.11 | −$0.10 | +9.09% | $1.5M | SEC |
| Q4 2023 | Feb 29, 2024 | −$0.12 | −$0.12 | −3.45% | $2.1M | SEC |
| Q3 2023 | Nov 7, 2023 | −$0.11 | −$0.12 | −7.14% | $4.7M | SEC |
| Q2 2023 | Aug 3, 2023 | −$0.11 | −$0.10 | +10.71% | $4.7M | SEC |
| Q1 2023 | May 4, 2023 | −$0.14 | −$0.10 | +26.47% | $6.7M | SEC |
| Q4 2022 | Mar 2, 2023 | −$0.13 | −$0.13 | +2.99% | $6.2M | SEC |
| Q3 2022 | Nov 9, 2022 | −$0.13 | −$0.12 | +6.25% | $6.0M | — |
| Q2 2022 | Aug 4, 2022 | −$0.12 | −$0.10 | +19.35% | $14.2M | — |
| Q1 2022 | May 5, 2022 | −$0.16 | −$0.11 | +31.25% | $12.6M | — |
| Q4 2021 | Mar 3, 2022 | −$0.19 | −$0.15 | +21.05% | $3.2M | — |
| Q3 2021 | Nov 4, 2021 | −$0.24 | −$0.24 | −0.84% | $3.3M | — |
| Q2 2021 | Aug 5, 2021 | −$0.23 | −$0.23 | −2.22% | $2.3M | — |
| Q1 2021 | May 5, 2021 | −$0.23 | −$0.21 | +9.25% | $2.1M | — |
| Q4 2020 | Mar 4, 2021 | −$0.22 | −$0.23 | −3.88% | $2.4M | — |
| Q3 2020 | Nov 5, 2020 | −$0.22 | −$0.27 | −25.00% | $1.5M | — |
Quarterly revenue
Frequently asked questions
When did Arbutus Biopharma (ABUS) last report earnings?
Arbutus Biopharma last reported on Aug 6, 2025, covering fiscal Q2 2025.
Did ABUS beat earnings estimates?
Yes. Arbutus Biopharma reported EPS of $0.01 for Q2 2025 against a −$0.05 estimate — a 121.05% beat.
How much revenue did ABUS report last quarter?
Arbutus Biopharma reported $10.7M in revenue for Q2 2025, against a consensus estimate of $1.6M.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.